Table 4 Base-case cost and outcomes when considering both direct and indirect effects
Outcome | PCV13 | PCV10 | Difference(PCV13 – PCV10) |
|---|---|---|---|
Total life-years | 605,602,153 | 605,586,870 | 15,283 |
  Total QALYs | 543,278,132 | 543,264,303 | 13,828 |
Annual number of cases | |||
  Myringotomy | 1,868 | 1,918 | −49.5 |
  Neurological impairment | 25.7 | 35. | −10.1 |
  Hearing loss | 47.8 | 66.5 | −18.7 |
  Death | 9,601.03 | 10,480.47 | −879.4 |
  Annual direct medical costs | $1,185,354,128 | $1,318,177,638 | –$132,823,511 |
Cost per QALY | PCV13 dominates PCV10 | ||